Novel Two-Part Drug Puts Cancer Cells Under Extreme Metabolic Stress by Hijacking Sugar and Blocking Fat
核心洞察
Researchers at The University of Texas at Austin developed an experimental compound that accelerates cancer cells' sugar consumption while simultaneously blocking their fat-based backup fuel supply.
The dual-action drug, described in Nature Chemical Biology, killed most cancer cells in an aggressive melanoma (搜索) mouse model while largely sparing noncancerous cells.
The compound, termed an "electrophile-drug conjugate" (EDC), acts as a fully chemical counterpart to antibody-drug conjugates and can target proteins inside cells.
Cancer cells have a voracious appetite for sugar, using it to fuel their rapid growth—a vulnerability that has led many scientists to pursue drugs that block cancer metabolism by cutting off the sugar supply. Now, a team led by researchers at The University of Texas at Austin reports in the journal Nature Chemical Biology that they have found a completely different approach: instead of starving cancer cells, they trick them into consuming even more sugar than usual while simultaneously blocking their backup fuel source, fat.
By attacking both fuel sources at once, the experimental drug puts cancer cells under so much metabolic stress that many of them die. The researchers demonstrated the drug's effectiveness at treating an aggressive form of melanoma (搜索) in mice.
"I like to think of this technology like a two-headed dragon. We are putting one part of the cell into overdrive while simultaneously weakening another part. It appears to be extremely potent," said Xiaolu (Lulu) Lim Ang Cambronne, associate professor of molecular biosciences at UT and co-corresponding author.
A Two-Pronged Attack on Cancer Metabolism
The drug consists of two functional parts. The targeting agent, a molecule called XJ-4-85 (搜索), acts on an enzyme called PFKL (搜索), speeding up glycolysis—the breakdown of sugar—inside cancer cells. After XJ-4-85 binds, it releases its payload, a compound that acts on another enzyme called CPT2 (搜索), which normally helps cells break down fatty acids for energy. By disrupting both of the cells' major energy sources at the same time, the drug shuts down cancer growth.
"The way this drug works was totally unexpected," said Xiaoding Jiang, a postdoctoral fellow in the Hsu Lab, who designed the molecule. "A lot of research was required to figure out what it was doing on the molecular level. We were also surprised to see how selectively it binds to cancer cells."
In laboratory experiments, the drug was effective against several types of human cancer cells, including melanoma (搜索), leukemia (搜索), breast cancer (搜索), lung cancer (搜索), liver cancer (搜索) and neuroblastoma (搜索). In the mice with melanoma, most cancer cells died, while non-cancerous cells were much less affected.
A Chemical Counterpart to Antibody-Drug Conjugates
Drugs that attack cancer with this kind of one-two punch are not entirely new. A growing class of compounds called antibody-drug conjugates (ADCs) use an antibody to target cancer cells, then deliver a payload of chemotherapy directly to the tumor. However, ADCs carry important limitations.
"Antibodies are difficult to make, and because they're so large they're only able to target proteins in the surface of cancer cells," said Ken Hsu, an associate professor of chemistry at UT and co-corresponding author. "We think of this new compound as a fully chemical counterpart to ADCs. They are much easier to manufacture. And because they are smaller, they are able to target even proteins that are inside cells."
Beyond this particular drug, the researchers say the work illustrates a broader approach for designing these two-part medicines, which they call "electrophile-drug conjugates" or EDCs. "They have the potential to be useful beyond cancer, for other kinds of diseases as well," Cambronne said.
Early-Stage Findings with a Long Road Ahead
The research remains in its early stages. Although the results are promising, much more laboratory testing is needed before the drug can be studied in people.
The study, titled "A covalent PFKL (搜索) activator suppresses tumor growth," was published on 5 August 2026 in Nature Chemical Biology (DOI: 10.1038/s41589-026-02289-9). The team members emphasized the importance of collaboration in making the discovery possible, bringing together experts from across UT and beyond. "This project took a village," said Hsu, a CPRIT Scholar.
The work was supported by the National Institutes of Health, the National Institute of General Medical Sciences, the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Washington Beckman Cryo-EM Center, West Virginia University's Visual Sciences CoBRE program, the Melanoma (搜索) Research Alliance, the Mark Foundation for Cancer Research, The Welch Foundation and Tito's Handmade Vodka.